Medtronic Issues FY23 Guidance; Plans To Form Independent Kidney Care-focused Medical Device Company

Medtronic plc (MDT) said global supply chain and COVID-19 controls in China created acute impacts to the company's results in the fourth quarter. Looking forward, the company expects recent and upcoming product launches to make a difference across its businesses in the coming fiscal year.

Medtronic expects fiscal 2023 non-GAAP EPS in the range of $5.53 to $5.65. Organic revenue growth is projected in the range of 4% to 5%. The company noted that, if recent foreign currency exchange rates hold, fiscal 2023 revenue would be negatively affected by approximately $1.0 billion to $1.1 billion. Analysts polled by Thomson Reuters expect the company to report profit per share of $5.82. Analysts' estimates typically exclude special items.

Fourth quarter non-GAAP was $1.52, up 2% from prior year. On average, 23 analysts polled by Thomson Reuters expected the company to report profit per share of $1.56, for the quarter.

The company's earnings totaled $1.49 billion, or $1.10 per share compared with $1.36 billion, or $1.00 per share, last year.

Worldwide revenue was $8.09 billion, a decrease of 1% as reported and an increase of 1% on an organic basis. Analysts on average had estimated $8.42 billion in revenue.

The company announced that effective May 25, 2022, the board approved an increase in cash dividend for the first quarter of fiscal year 2023, raising the quarterly amount to $0.68 per ordinary share. This would translate into an annual amount of $2.72 per ordinary share, an 8% increase from the prior $2.52.

Separately, Medtronic plc and DaVita Inc. (DVA) announced the intent to form a new, independent kidney care-focused medical device company. Medtronic will contribute its Renal Care Solutions business including the current product portfolio, product pipeline, and global manufacturing R&D teams and facilities.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ice Cream maker Ben & Jerry's reportedly filed a lawsuit against parent and British consumer giant Unilever to stop the sale of its Israeli business to a local license-holder Avi Zinger. The company alleged that the decision was made without the approval of its independent board. The judge reportedly denied Ben & Jerry's application for a temporary restraining order against Unilever. J&M Foods is recalling certain Lavender Shortbread Cookies sold through department store chain Target Corp. due to undeclared allergens, the U.S. Food and Drug Administration said. These packages were erroneously packed with Chocolate Chip Cookies and do not disclose the presence of a possible allergen, such as soy or eggs. A multi-state listeria outbreak that has killed one and sickened at least 23 others has been linked to Florida -based Big Olaf Creamery brand ice cream, according to the Centers for Disease Control and Prevention or CDC. The outbreak strain has been reported from 10 states, resulting in 22 hospitalizations. One death has been reported from Illinois.
Follow RTT